Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 15/20 | 0.61 |
| ▸ | HASPIN | Q8TF76 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17102959 | 0.82 | DYRK1A (0.84) | DYRK1AHASPINHTR2AHTR2CMAOA | |
| SCHEMBL17502379 | 0.82 | DYRK1A (0.80) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL27921179 | 0.81 | DYRK1A (0.65) | DYRK1AHASPINHTR2AHTR2CACHE | |
| SCHEMBL17502366 | 0.81 | DYRK1A (0.78) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL17102950 | 0.80 | DYRK1A (0.77) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL27917535 | 0.80 | DYRK1A (0.76) | DYRK1AHASPINHTR2AHTR2CMAOA | |
| Benzene SCHEMBL27921298 | 0.80 | DYRK1A (0.58) | DYRK1AHASPINHTR2AHTR2CACHE | |
| SCHEMBL23150413 | 0.79 | DYRK1A (0.74) | DYRK1AHASPINHTR2AHTR2CACHE | |
| SCHEMBL20340616 | 0.79 | DYRK1A (0.88) | DYRK1AHASPINHTR2AHTR2CACHE | |
| SCHEMBL27939882 | 0.79 | DYRK1A (0.73) | DYRK1AHASPINHTR2AHTR2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9168247-B2 | Beta carboline derivatives useful in the treatment of proliferative disorders | FACULTES UNIVERSITAIRES NOTRE DAME DE LA PAIX (BE) | 2015-10-27 | — | — | US | disclosed |
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2014-01-02 | — | — | US | disclosed |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005220-A9 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885HASPIN 1835/4885HTR2A 2186/4885 |
| US-20130116273-A1 | BETA CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CCNI, CCNA1, BRCA1 | DYRK1A 2151/4885HASPIN 1835/4885HTR2A 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.